CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage
biopharmaceutical company developing T cell-enabled vaccines and
immunotherapies, announced today that it will hold a conference call and
live audio webcast on August 6, 2014 at 9:00 a.m. ET to discuss
financial results for the quarter ended June 30, 2014. The presentation,
hosted by Genocea president and chief executive officer Chip Clark and
chief financial officer Jonathan Poole, will also provide an update on
the company's recent progress and upcoming milestones.
Interested participants and investors may access the conference call by
dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and
refer to conference ID number 77088780. To join the live webcast please
visit the investor relations section of the Genocea website at http://ir.genocea.com.
A webcast replay will be available on the Genocea website beginning
approximately two hours after the event, and will be archived for 30
Genocea is harnessing the power of T cell immunity to develop the next
generation of vaccines and immunotherapies. T cells are increasingly
recognized as a critical element of protective immune responses to a
wide range of diseases, but are difficult to target using traditional
discovery methods. Genocea is able to identify protective T cell
antigens in humans using ATLAS™, its proprietary technology platform,
potentially enabling vaccines and immunotherapies to address critical
patient needs. Genocea's pipeline of novel clinical stage T cell-enabled
product candidates includes GEN-003 for HSV-2 therapy, GEN-004 to
prevent infections caused by pneumococcus, and earlier-stage programs in
chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy. For more
information, please visit the company's website at www.genocea.com.
Source: Genocea Biosciences, Inc.